News
Brand Events
Spirit Scientific BioTech Wins Ministry of Economic Affairs'”Startup Award,” Innovative Operating Strategy Recognized
Nov 19, 2025, The 24th "Startup Award" ceremony, hosted by the Ministry of Economic Affairs (MOEA), was grandly held yesterday at the NTUH International Convention Center. Spirit Scientific BioTech (7790), which focuses on precision regenerative medicine, was honored with the "Startup Award" in the Technology Industry category, demonstrating recognition for its technical innovation and outstanding operating performance.Spirit Scientific BioTech stated that it holds the core technology of Biological Material Lyophilization Technology (BMLT ®) and has developed an innovative service model: the Biofoundry™ Diamond-Grade Lyophilization Preparation Service. This model provides standardized and
Spirit Scientific gains recognition with double bronze for 2 patents at Innotech Expo, highlighting solutions for PRP limitations at Taiwanese Orthopaedic Association
Spirit Scientific Wins Awards at 2025 Taiwan Innotech Expo, Highlighting Precision Regenerative Medicine Innovations Spirit Scientific (7790), a company focusing on precision regenerative medicine, recently showcased two innovative patented technologies at the 2025 Taiwan Innotech Expo (TIE): "A Growth Factor-Rich Dry Powder for Use in Alleviating Inflammation or Injury" and "A Platelet-Containing Composition and Method for Preparing the Same." Both technologies earned the company Bronze Medals in the invention competition. Spirit Scientific stated that both patents are based on the company's core Biological Material Lyophilization Technology (BMLT). This achievement demonstrates
Spirit Scientific Biotech: Innovating regenerative medicine by turning biomaterials into pharmaceuticals
Spirit Scientific Biotech is participating in the BIO Asia-Taiwan exhibition for the first time. The well-known media outlet conducted a interview video with us. Steven D. Lin, co-founder and chairman of Spirit Scientific Biotech, made his first appearance at BIO Asia-Taiwan, sharing the company's innovative plans in the field of regenerative medicine. Spirit Scientific Biotech focuses on the pharmaceutical and standardization of biomaterials. Their core technology, BMLT, can significantly improve the stability and shelf life of biomaterials. Their first product, Platelet Lyphoilized Treatment (PLT), is currently the safest
Spirit Scientific biotech debuts at BIO Asia with key lyophilization technology, enabling precise PRP medicine
Spirit Scientific biotech, leader in regenerative medicine, made its debut at BIO Asia-Taiwan 2025. The company showcased its core BMLT®, which transforms biomaterials into stable, quantifiable, and lyophilized forms. This technology's key application is in enhancing traditional PRP (platelet-rich plasma) therapy. By preparing a precise, consistent Platelet Lyophilized Treatment(PLT) product, Spirit Scientific biotech eliminates the variability of standard PRP injections. With over 36,000 cases and partnerships with more than 1,300 medical institutions, the company is now seeking new collaborations to expand its technology's applications. Spirit Scientific biotech has also established
Spirit Scientific biotech’s PLT preparation service grabs attention at tokyo regenerative medicine expo
Spirit Scientific biotech Expands Globally, Shines at Tokyo and BIO Asia Expos Spirit Scientific biotech, a company focused on standardized regenerative medicine, showcased its innovative BMLT® at 2 major expos: the Regenerative Medicine Expo TOKYO and the upcoming BIO Asia-Taiwan. The company's core technology allows it to transform biological materials into stable, precise, and easy-to-use lyophilized products like Platelet Lyophilized Treatment(PLT). This offers a major advantage over traditional therapies like PRP, which can be inconsistent. With over 36,000 cases in Taiwan and a newly opened lab in Japan, Spirit Scientific
Taiwanese biotech Spirit Scientific expands into Japan with advanced regenerative medicine technology
Spirit Scientific, a regenerative medicine startup from New Taipei City, Taiwan, officially entered the Japanese market in 2023. The company focuses on Platelet-Rich Plasma (PRP) therapy, leveraging its innovative platelet lyophilization technology for long-term preservation as a key competitive advantage. Their goal is to popularize and advance the clinical application of this treatment. Strategic Expansion and Growth Spirit Scientific chose Japan as its first international market due to its well-established regulatory framework for regenerative medicine, which provides a supportive environment for clinical and commercial applications. The company also recognized Japan's
Spirit Scientific launches platelet-derived cellular signal factors lyophilization services, driving new momentum in biotechnology
Spirit Scientific (7790), a Taiwanese regenerative medicine startup, has launched its autologous platelet-derived cellular signal factors lyophilization services. This innovation follows the recent legislative approval of the Regenerative Medicine Law and Regulations in Taiwan, aligning with the "Healthy Taiwan" policy and boosting the competitiveness of the biotech and medical industry. Cellular signal factors, nanoscale vesicles secreted by cells, act as intercellular messengers containing proteins, mRNA, and other biomolecules. They play crucial roles in tissue repair, immune regulation, and more, offering significant potential in diagnostics and therapeutics. Leveraging nearly a decade
Announcement: Transition to new corporate image and coexistence of old and new packaging
Dear Valued Customers and Partners, Thank you for your continuous support and trust. To enhance our brand image and service quality, we have been updating our corporate image and logo this year, reflecting our spirit of innovation and pursuit of excellence. While embracing this brand upgrade, we are also deeply committed to environmental responsibility, energy conservation, and carbon reduction. As part of this commitment, our product packaging and promotional materials will be phased out gradually. To prevent the waste of resources associated with a one-time disposal of old packaging,
12/03 思必瑞特總經理-林道隆再次受邀參與台新證券舉辦之「2021生技投資高峰論壇」 專家分析後疫情時代 生醫大未來
台新證券舉辦2021生技投資高峰論壇探討生醫產業投資趨勢，由左到右為台新投顧總經理李鎮宇、保瑞藥業董事長盛保熙、台新證券董事長郭嘉宏、醫揚科技美洲總經理莊富鈞、思必瑞特總經理林道隆。 全球疫情正面臨變種病毒侵襲，臺灣在政府及民間的共同努力下，抗疫的成果亮眼。台新證券上週五 (12/3) 於南港展覽館舉辦「2021 生技投資高峰論壇」，邀請到保瑞藥業董事長盛保熙、思必瑞特生技總經理林道隆、醫揚科技美洲總經理莊富鈞以及台新投顧總經理李鎮宇，針對臺灣生醫產業未來走向，並展望後疫情時代，臺灣生技業何去何從? 以及生醫產業策略如何發展等主題共同探討，一起掌握未來投資新趨勢。 台新證券董事長郭嘉宏致詞時表示，此次論壇以四大議題進行探討，分別為生技投資、CDMO(委託開發暨製造服務) 未來趨勢、再生醫療技術及數位醫療科技創新，精闢分析產業動向，為投資人掌握新商機。論壇開場首先由台新投顧總經理李鎮宇博士以台股投資的方向，進行「後疫情時代、生醫大未來」探討。李鎮宇演講中提到，未來主要著眼於 CDMO 產業有望複製晶圓代工的發展軌跡、算力演進與定序技術為精準醫療奠定發展基礎，未來癌症治療將邁向精準時代、元宇宙應用為醫療產業帶來突破、半導體開創生醫產業無限可能等動態。 再者由國際級 CDMO 大廠保瑞藥業董事長盛保熙精闢分析 CDMO 發展新趨勢，並說明保瑞藥業透過精準與策略性的併購，逐步佈局完整劑型生產線，擴展集團規模與國際代工能量，成為一家國際性的 CDMO 大廠。盛保熙在會中也指出 CDMO 產業趨勢與展望及臺灣 CDMO 的機會，也因為產業高成長率及一條龍 CDMO 需求高，再透過併購 (M&A) 或內生增長的積極成長策略，未來勢必引爆一股投資新熱潮。 接續由再生醫學技術領域的領導廠商思必瑞特總經理林道隆分享針對再生醫療技術的突破。思必瑞特公司致力於血液再生工程服務，並透過專利技術克服了傳統血小板製品應用於再生醫療所受的限制，是全球再生醫學與細胞療法技術領域之領導者。林道隆以再生醫學的宗旨，在論壇中分析市場變化與應用，精準引導成未來新趨勢。 論壇壓軸由 AI 醫療設備大廠醫揚科技美洲總經理莊富鈞暢談「數位醫療科技創新的新契機」，該公司以醫療用電腦研發、製造及銷售為主，與全球各大醫療大廠合作開發 AI 新技術，為業界技術領先的廠商。莊富鈞在論壇中分享在智慧醫療物聯網 (AIoMT)、行動照護系統、遠距居家照護醫療等領域的數位醫療科技創新所帶來的新契機。 https://news.cnyes.com/news/id/4781104
2021 第三屆世界美容醫學高峰會亞洲大會&第八屆臺灣皮膚科美容醫學學術研討會活動花絮側拍
110年5月01-02日為AMWC Asia &TDAC【第三屆世界美容醫學高峰會亞洲大會&第八屆臺灣皮膚科美容醫學學術研討會】，思必瑞特生技當然也不缺席，我們在 C20 (3F) 設有專屬的展位，並安排實力堅強的專業團隊，研討會第二天 (5/2)，很榮幸邀請立悅皮膚科診所莊德揚院長帶來的有關PLT應用在臉部演講，演講精采，賓客盈門。
110年3月14日復健科年會 超越復健科診所王薏茜醫師演講「血小板製劑在復健科的應用」
台灣復建醫學會110年度會員大會暨聯合學術研討會於 3 月 14 日 (星期日) 12時10 分，在午餐座談會，特別邀請超越復建科診所王薏茜醫師分享「The clinical Application of PLT in Rehabilitation Medicine 血小板製劑在復健科的應用」講題。#王薏茜#血小板#PRP#PLT#再生醫學#復健科#小面關節炎#超越復健科診所 PRP（Platelet Rich Plasma）全名為高濃度血小板血漿 ，在學理上其富含高濃度能啟動傷口組織修復機制的多種生長因子，有效應用在骨科、復健科、心臟手術、整形美容以及運動醫學等領域，透過自體血液經離心後留下純淨PRP，刺激細胞分泌生長因子，促進膠原蛋白增生、組織修復、表皮組織生長、調節肌肉細胞再生等生成，並可減緩術後、創傷傷疤的形成。 台灣復健醫學會110年度會員大會暨聯合學術研討會於 3 月 14 日 (星期日) 12時10 分，在午餐座談會，特別邀請超越復建科診所王薏茜醫師分享「The Clinical Application of PLT in Rehabilitation Medicine 血小板製劑在復健科的應用」講題。PRP 的製備來自全血進行離心分離，離心分離後可區分成 3 層，由底層往上分別是：紅血球 (45% of whole blood)、buffy coat : 白血球和血小板 (＜1% of whole blood)、血漿 (55% of whole blood)。回收高濃度血小板血漿，需要考慮 3 個會影響血小板回收率與血小板品質等因素：抗凝血 (anti-coagulation)、分離膠體 (separation gel)、活化 (activation)，因此如何獲得高品質的高濃度血小板血漿是一個值得思考的方向。 王薏茜醫師介紹思必瑞特生技的血小板凍晶專利技術 (SSLab PLT, Platelet-Lyophilized Treatment)，為一種新穎血小板萃取技術，抽取 250 毫升全血，送至思必瑞特分子醫學實驗室經過離心分離、量化、真空冷凍乾燥以及伽馬射線滅菌，最後得到每瓶含有 10億顆血小板乾粉並且檢附生長因子濃度檢測報告書協助臨床治療用量參考。王醫師在座談會上也分享自身使用PLT經驗以及PLT臨床應用小面關節炎的治療經驗。 在這場「The Clinical Application of PLT in Rehabilitation Medicine 血小板製劑在復健科的應用」午餐講座中，王薏茜醫師精彩連連的演講深入淺出剖析傳統血小板製劑、再生醫療全球未來發展、SSLab PLT血小板凍晶的優勢以及SSLab PLT在小面關節炎的治療成效與好處，讓大家在享用餐點同時，吸取最新穎、最夯的再生醫學新知~
